HIV-1 entry, inhibitors, and resistance

Viruses

Volumn 2, Issue 5, 2010, Pages 1069-1105

  Lobritz, Michael A ^a   Ratcliff, Annette N ^a   Arts, Eric J ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CCR5; Envelope; Gp120; Gp41; HIV 1; Maraviroc; V3 loop; Vicriviroc

Indexed keywords

4 [(4 BROMOPHENYL)(ETHOXYIMINO)METHYL] 1' [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4' METHYL 1,4' BIPIPERIDINE; 4 [1 [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4 METHYL 4 PIPERIDINYL] 2 METHYL 1 [1 [4 (TRIFLUOROMETHYL)PHENYL]ETHYL]PIPERAZINE; 8 [4 (2 BUTOXYETHOXY)PHENYL] 1,2,3,4 TETRAHYDRO 1 ISOBUTYL N [4 (1 PROPYL 1H IMIDAZOL 5 YLMETHYLSULFINYL)PHENYL] 1 BENZAZOCINE 5 CARBOXAMIDE; ABACAVIR; AMPRENAVIR; APLAVIROC; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; MARAVIROC; NELFINAVIR; NEVIRAPINE; RALTEGRAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VICRIVIROC; VILEAD; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLOSTERISM; BINDING AFFINITY; BINDING SITE; COMPLEX FORMATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYDROPHOBICITY; MEMBRANE FUSION; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RECEPTOR AFFINITY; REVERSE TRANSCRIPTION; REVIEW; SALVAGE THERAPY; VIRAL TROPISM; VIRUS ATTACHMENT; VIRUS CORE; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS RESISTANCE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79952085104     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v2051069     Document Type: Review

References (168)

1. Mansky, L.M.; Temin, H.M. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol. 1995, 69, 5087-5094.
2. Bartlett, J.G.; Gallant, J.E.; Pham P. Medical Management of HIV Infection, 15th ed.; Knowledge Source Solutions: Baltimore, MD, USA, 2009.
3. U.S. Food and Drug Administration. Approved HIV-1 Antiretrovirals. http://www.fda.gov (accessed December 3, 2009).
4. Dalgleish, A.G.; Beverley, P.C.; Clapham, P.R.; Crawford, D.H.; Greaves, M.F.; Weiss, R.A. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984, 312, 763-767.
5. Berger, E.A.; Murphy, P.M.; Farber, J.M. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 1999, 17, 657-700.
6. Stein, B.S.; Gowda, S.D.; Lifson, J.D.; Penhallow, R.C.; Bensch, K.G.; Engleman, E.G. pH-independent HIV entry into CD4-positive T cells via virus envelope fusion to the plasma membrane. Cell 1987, 49, 659-668.
7. Miyauchi, K.; Kim, Y.; Latinovic, O.; Morozov, V.; Melikyan, G.B. HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell 2009, 137, 433-444.
8. Daecke, J.; Fackler, O.T.; Dittmar, M.T.; Krausslich, H.G. Involvement of clathrin-mediated endocytosis in human immunodeficiency virus type 1 entry. J. Virol. 2005, 79, 1581-1594.
9. Wyatt, R.; Sodroski, J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998, 280, 1884-1888.
10. Doms, R.W.; Lamb, R.A.; Rose, J.K.; Helenius, A. Folding and assembly of viral membrane proteins. Virology 1993, 193, 545-562.
11. Earl, P.L.; Moss, B.; Doms, R.W. Folding, interaction with GRP78-BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope protein. J. Virol. 1991, 65, 2047-2055.
12. Moulard, M.; Decroly, E. Maturation of HIV envelope glycoprotein precursors by cellular endoproteases. Biochim. Biophys. Acta 2000, 1469, 121-132.
13. Colman, P.M.; Lawrence, M.C. The structural biology of type I viral membrane fusion. Nat. Rev. Mol. Cell Biol. 2003, 4, 309-319.
14. McDougal, J.S.; Nicholson, J.K.; Cross, G.D.; Cort, S.P.; Kennedy, M.S.; Mawle, A.C. Binding of the human retrovirus HTLV-III/LAV/ARV/HIV to the CD4 (T4) molecule: conformation dependence, epitope mapping, antibody inhibition, and potential for idiotypic mimicry. J. Immunol. 1986, 137, 2937-2944.
15. Zhou, T.; Xu, L.; Dey, B.; Hessell, A.J.; Van, R.D.; Xiang, S.H.; Yang, X.; Zhang, M.Y.; Zwick, M.B.; Arthos, J.; Burton, D.R.; Dimitrov, D.S.; Sodroski, J.; Wyatt, R.; Nabel, G.J.; Kwong, P.D. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007, 445, 732-737.
16. Bieniasz, P.D.; Fridell, R.A.; Aramori, I.; Ferguson, S.S.; Caron, M.G.; Cullen, B.R. HIV-1-induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR-5 co-receptor. EMBO J. 1997, 16, 2599-2609.
17. Kwong, P.D.; Wyatt, R.; Robinson, J.; Sweet, R.W.; Sodroski, J.; Hendrickson, W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393, 648-659.
18. Rizzuto, C.; Sodroski, J. Fine definition of a conserved CCR5-binding region on the human immunodeficiency virus type 1 glycoprotein 120. AIDS Res. Hum. Retroviruses 2000, 16, 741-749.
19. Sattentau, Q.J.; Moore, J.P. Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J. Exp. Med. 1991, 174, 407-415.
20. Trkola, A.; Dragic, T.; Arthos, J.; Binley, J.M.; Olson, W.C.; Allaway, G.P.; Cheng-Mayer, C.; Robinson, J.; Maddon, P.J.; Moore, J.P. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 1996, 384, 184-187.
21. Gallaher, W.R. Detection of a fusion peptide sequence in the transmembrane protein of human immunodeficiency virus. Cell 1987, 50, 327-328.
22. Harter, C.; James, P.; Bachi, T.; Semenza, G.; Brunner, J. Hydrophobic binding of the ectodomain of influenza hemagglutinin to membranes occurs through the fusion peptide. J. Biol. Chem. 1989, 264, 6459-6464.
23. Melikyan, G.B.; Markosyan, R.M.; Hemmati, H.; Delmedico, M.K.; Lambert, D.M.; Cohen, F.S. Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J. Cell Biol. 2000, 151, 413-423.
24. Myszka, D.G.; Sweet, R.W.; Hensley, P.; Brigham-Burke, M.; Kwong, P.D.; Hendrickson, W.A.; Wyatt, R.; Sodroski, J.; Doyle, M.L. Energetics of the HIV gp120-CD4 binding reaction. Proc. Natl. Acad. Sci. U.S.A 2000, 97, 9026-9031.
25. Weissenhorn, W.; Wharton, S.A.; Calder, L.J.; Earl, P.L.; Moss, B.; Aliprandis, E.; Skehel, J.J.; Wiley, D.C. The ectodomain of HIV-1 env subunit gp41 forms a soluble, alpha-helical, rod-like oligomer in the absence of gp120 and the N-terminal fusion peptide. EMBO J. 1996, 15, 1507-1514.
26. Chambers, P.; Pringle, C.R.; Easton, A.J. Heptad repeat sequences are located adjacent to hydrophobic regions in several types of virus fusion glycoproteins. J. Gen. Virol. 1990, 71, 3075-3080.
27. Delwart, E.L.; Mosialos, G.; Gilmore, T. Retroviral envelope glycoproteins contain a leucine zipper-like repeat. AIDS Res. Hum. Retroviruses 1990, 6, 703-706.
28. Gallaher, W.R.; Ball, J.M.; Garry, R.F.; Griffin, M.C.; Montelaro, R.C. A general model for the transmembrane proteins of HIV and other retroviruses. AIDS Res. Hum. Retroviruses 1989, 5, 431-440.
29. Chan, D.C.; Fass, D.; Berger, J.M.; Kim, P.S. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997, 89, 263-273.
30. Weissenhorn, W.; Dessen, A.; Harrison, S.C.; Skehel, J.J.; Wiley, D.C. Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997, 387, 426-430.
31. Smith, D.H.; Byrn, R.A.; Marsters, S.A.; Gregory, T.; Groopman, J.E.; Capon, D.J. Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen. Science 1987, 238, 1704-1707.
32. Deen, K.C.; McDougal, J.S.; Inacker, R.; Folena-Wasserman, G.; Arthos, J.; Rosenberg, J.; Maddon, P.J.; Axel, R.; Sweet, R. W. A soluble form of CD4 (T4) protein inhibits AIDS virus infection. Nature 1988, 331, 82-84.
33. Traunecker, A.; Luke, W.; Karjalainen, K. Soluble CD4 molecules neutralize human immunodeficiency virus type 1. Nature 1988, 331, 84-86.
34. Hussey, R.E.; Richardson, N.E.; Kowalski, M.; Brown, N.R.; Chang, H.C.; Siliciano, R.F.; Dorfman, T.; Walker, B.; Sodroski, J.; Reinherz, E.L. A soluble CD4 protein selectively inhibits HIV replication and syncytium formation. Nature 1988, 331, 78-81.
35. Fisher, R.A.; Bertonis, J.M.; Meier, W.; Johnson, V.A.; Costopoulos, D.S.; Liu, T.; Tizard, R.; Walker, B.D.; Hirsch, M.S.; Schooley, R.T. HIV infection is blocked in vitro by recombinant soluble CD4. Nature 1988, 331, 76-78.
36. Watanabe, M.; Reimann, K.A.; DeLong, P.A.; Liu, T.; Fisher, R.A.; Letvin, N.L. Effect of recombinant soluble CD4 in rhesus monkeys infected with simian immunodeficiency virus of macaques. Nature 1989, 337, 267-270.
37. Schooley, R.T.; Merigan, T.C.; Gaut, P.; Hirsch, M.S.; Holodniy, M.; Flynn, T.; Liu, S.; Byington, R.E.; Henochowicz, S.; Gubish, E. Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial. Ann. Intern. Med. 1990, 112, 247-253.
38. Traunecker, A.; Schneider, J.; Kiefer, H.; Karjalainen, K. Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules. Nature 1989, 339, 68-70.
39. Daar, E.S.; Li, X.L.; Moudgil, T.; Ho, D.D. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc. Natl. Acad. Sci. U.S.A 1990, 87, 6574-6578.
40. Ivey-Hoyle, M.; Culp, J.S.; Chaikin, M.A.; Hellmig, B.D.; Matthews, T.J.; Sweet, R.W.; Rosenberg, M. Envelope glycoproteins from biologically diverse isolates of immunodeficiency viruses have widely different affinities for CD4. Proc. Natl. Acad. Sci. U. S. A 1991, 88, 512-516.
41. Hodges, T.L.; Kahn, J.O.; Kaplan, L.D.; Groopman, J.E.; Volberding, P.A.; Amman, A.J.; Arri, C.J.; Bouvier, L.M.; Mordenti, J.; Izu, A.E.;. Phase 1 study of recombinant human CD4-immunoglobulin G therapy of patients with AIDS and AIDS-related complex. Antimicrob. Agents Chemother. 1991, 35, 2580-2586.
42. Collier, A.C.; Coombs, R.W.; Katzenstein, D.; Holodniy, M.; Gibson, J.; Mordenti, J.; Izu, A.E.; Duliege, A.M.; Ammann, A.J.; Merigan, T.;. Safety, pharmacokinetics, and antiviral response of CD4-immunoglobulin G by intravenous bolus in AIDS and AIDS-related complex. J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol. 1995, 10, 150-156.
43. Brinchmann, J.E.; Gaudernack, G.; Vartdal, F. CD8+ T cells inhibit HIV replication in naturally infected CD4+ T cells. Evidence for a soluble inhibitor. J. Immunol. 1990, 144, 2961-2966.
44. Cocchi, F.; DeVico, A.L.; Garzino-Demo, A.; Arya, S.K.; Gallo, R.C.; Lusso, P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995, 270, 1811-1815.
45. Murphy, P.M.; Baggiolini, M.; Charo, I.F.; Hebert, C.A.; Horuk, R.; Matsushima, K.; Miller, L. H.; Oppenheim, J.J.; Power, C.A. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol. Rev. 2000, 52, 145-176.
46. Feng, Y.; Broder, C.C.; Kennedy, P.E.; Berger, E.A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996, 272, 872-877.
47. Oberlin, E.; Amara, A.; Bachelerie, F.; Bessia, C.; Virelizier, J.L.; Arenzana-Seisdedos, F.; Schwartz, O.; Heard, J.M.; Clark-Lewis, I.; Legler, D.F.; Loetscher, M.; Baggiolini, M.; Moser, B. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 1996, 382, 833-835.
48. Bleul, C.C.; Farzan, M.; Choe, H.; Parolin, C.; Clark-Lewis, I.; Sodroski, J.; Springer, T.A. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996, 382, 829-833.
49. Alkhatib, G.; Combadiere, C.; Broder, C.C.; Feng, Y.; Kennedy, P.E.; Murphy, P.M.; Berger, E.A. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996, 272, 1955-1958.
50. Choe, H.; Farzan, M.; Sun, Y.; Sullivan, N.; Rollins, B.; Ponath, P.D.; Wu, L.; Mackay, C.R.; LaRosa, G.; Newman, W.; Gerard, N.; Gerard, C.; Sodroski, J. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996, 85, 1135-1148.
51. Deng, H.; Liu, R.; Ellmeier, W.; Choe, S.; Unutmaz, D.; Burkhart, M.; Di, M.P.; Marmon, S.; Sutton, R.E.; Hill, C.M.; Davis, C.B.; Peiper, S.C.; Schall, T.J.; Littman, D.R.; Landau, N.R. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996, 381, 661-666.
52. Dragic, T.; Litwin, V.; Allaway, G.P.; Martin, S.R.; Huang, Y.; Nagashima, K.A.; Cayanan, C.; Maddon, P.J.; Koup, R.A.; Moore, J.P.; Paxton, W.A. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996, 381, 667-673.
53. Hill, C.M.; Deng, H.; Unutmaz, D.; Kewalramani, V.N.; Bastiani, L.; Gorny, M.K.; Zolla-Pazner, S.; Littman, D.R. Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor. J. Virol. 1997, 71, 6296-6304.
54. Doranz, B.J.; Rucker, J.; Yi, Y.; Smyth, R.J.; Samson, M.; Peiper, S.C.; Parmentier, M.; Collman, R.G.; Doms, R.W. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996, 85, 1149-1158.
55. Edinger, A.L.; Hoffman, T.L.; Sharron, M.; Lee, B.; Yi, Y.; Choe, W.; Kolson, D.L.; Mitrovic, B.; Zhou, Y.; Faulds, D.; Collman, R.G.; Hesselgesser, J.; Horuk, R.; Doms, R.W. An orphan seven-transmembrane domain receptor expressed widely in the brain functions as a coreceptor for human immunodeficiency virus type 1 and simian immunodeficiency virus. J. Virol. 1998, 72, 7934-7940.
56. Farzan, M.; Choe, H.; Martin, K.; Marcon, L.; Hofmann, W.; Karlsson, G.; Sun, Y.; Barrett, P.; Marchand, N.; Sullivan, N.; Gerard, N.; Gerard, C.; Sodroski, J. Two orphan seven- transmembrane segment receptors which are expressed in CD4-positive cells support simian immunodeficiency virus infection. J. Exp. Med. 1997, 186, 405-411.
57. He, J.; Chen, Y.; Farzan, M.; Choe, H.; Ohagen, A.; Gartner, S.; Busciglio, J.; Yang, X.; Hofmann, W.; Newman, W.; Mackay, C.R.; Sodroski, J.; Gabuzda, D. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature 1997, 385, 645-649.
58. Liao, F.; Alkhatib, G.; Peden, K.W.; Sharma, G.; Berger, E.A.; Farber, J.M. STRL33, A novel chemokine receptor-like protein, functions as a fusion cofactor for both macrophage-tropic and T cell line-tropic HIV-1. J. Exp. Med. 1997, 185, 2015-2023.
59. Berger, E.A.; Doms, R.W.; Fenyo, E.M.; Korber, B.T.; Littman, D.R.; Moore, J.P.; Sattentau, Q.J.; Schuitemaker, H.; Sodroski, J.; Weiss, R.A. A new classification for HIV-1. Nature 1998, 391, 240.
60. Connor, R.I.; Sheridan, K.E.; Ceradini, D.; Choe, S.; Landau, N.R. Change in coreceptor use correlates with disease progression in HIV-1--infected individuals. J. Exp. Med. 1997, 185, 621-628.
61. Tersmette, M.; de Goede, R.E.; Al, B.J.; Winkel, I.N.; Gruters, R.A.; Cuypers, H.T.; Huisman, H.G.; Miedema, F. Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. J. Virol. 1988, 62, 2026-2032.
62. Schuitemaker, H.; Koot, M.; Kootstra, N.A.; Dercksen, M.W.; de Goede, R.E.; van Steenwijk, R.P.; Lange, J.M.; Schattenkerk, J.K.; Miedema, F.; Tersmette, M. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J. Virol. 1992, 66, 1354-1360.
63. Dean, M.; Carrington, M.; Winkler, C.; Huttley, G.A.; Smith, M.W.; Allikmets, R.; Goedert, J.J.; Buchbinder, S.P.; Vittinghoff, E.; Gomperts, E.; Donfield, S.; Vlahov, D.; Kaslow, R.; Saah, A.; Rinaldo, C.; Detels, R.; O'Brien, S.J. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996, 273, 1856-1862.
64. Huang, Y.; Paxton, W.A.; Wolinsky, S.M.; Neumann, A.U.; Zhang, L.; He, T.; Kang, S.; Ceradini, D.; Jin, Z.; Yazdanbakhsh, K.; Kunstman, K.; Erickson, D.; Dragon, E.; Landau, N.R.; Phair, J.; Ho, D.D.; Koup, R.A. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat. Med. 1996, 2, 1240-1243.
65. Liu, R.; Paxton, W.A.; Choe, S.; Ceradini, D.; Martin, S.R.; Horuk, R.; MacDonald, M.E.; Stuhlmann, H.; Koup, R.A.; Landau, N.R. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996, 86, 367-377.
66. Michael, N.L.; Chang, G.; Louie, L.G.; Mascola, J.R.; Dondero, D.; Birx, D.L.; Sheppard, H.W. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat. Med. 1997, 3, 338-340.
67. Samson, M.; Libert, F.; Doranz, B.J.; Rucker, J.; Liesnard, C.; Farber, C.M.; Saragosti, S.; Lapoumeroulie, C.; Cognaux, J.; Forceille, C.; Muyldermans, G.; Verhofstede, C.; Burtonboy, G.; Georges, M.; Imai, T.; Rana, S.; Yi, Y.; Smyth, R.J.; Collman, R.G.; Doms, R.W.; Vassart, G.; Parmentier, M. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996, 382, 722-725.
68. Zimmerman, P.A.; Buckler-White, A.; Alkhatib, G.; Spalding, T.; Kubofcik, J.; Combadiere, C.; Weissman, D.; Cohen, O.; Rubbert, A.; Lam, G.; Vaccarezza, M.; Kennedy, P.E.; Kumaraswami, V.; Giorgi, J.V.; Detels, R.; Hunter, J.; Chopek, M.; Berger, E.A.; Fauci, A.S.; Nutman, T.B.; Murphy, P.M. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol. Med. 1997, 3, 23-36.
69. An, P.; Martin, M.P.; Nelson, G.W.; Carrington, M.; Smith, M.W.; Gong, K.; Vlahov, D.; O'Brien, S.J.; Winkler, C.A. Influence of CCR5 promoter haplotypes on AIDS progression in African-Americans. AIDS 2000, 14, 2117-2122.
70. Martin, M.P.; Dean, M.; Smith, M.W.; Winkler, C.; Gerrard, B.; Michael, N.L.; Lee, B.; Doms, R.W.; Margolick, J.; Buchbinder, S.; Goedert, J.J.; O'Brien, T.R.; Hilgartner, M.W.; Vlahov, D.; O'Brien, S.J.; Carrington, M. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 1998, 282, 1907-1911.
71. McDermott, D.H.; Zimmerman, P.A.; Guignard, F.; Kleeberger, C.A.; Leitman, S.F.; Murphy, P.M. CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). Lancet 1998, 352, 866-870.
72. Ometto, L.; Bertorelle, R.; Mainardi, M.; Zanchetta, M.; Tognazzo, S.; Rampon, O.; Ruga, E.; Chieco-Bianchi, L.; De, R.A. Polymorphisms in the CCR5 promoter region influence disease progression in perinatally human immunodeficiency virus type 1-infected children. J. Infect. Dis. 2001, 183, 814-818.
73. Thio, C.L.; Astemborski, J.; Bashirova, A.; Mosbruger, T.; Greer, S.; Witt, M.D.; Goedert, J.J.; Hilgartner, M.; Majeske, A.; O'Brien, S.J.; Thomas, D.L.; Carrington, M. Genetic protection against hepatitis B virus conferred by CCR5Delta32: Evidence that CCR5 contributes to viral persistence. J. Virol. 2007, 81, 441-445.
74. Glass, W.G.; McDermott, D.H.; Lim, J.K.; Lekhong, S.; Yu, S.F.; Frank, W.A.; Pape, J.; Cheshier, R.C.; Murphy, P.M. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J. Exp. Med. 2006, 203, 35-40.
75. Hartley, O.; Klasse, P.J.; Sattentau, Q.J.; Moore, J.P. V3: HIV's switch-hitter. AIDS Res. Hum. Retroviruses 2005, 21, 171-189.
76. Nabatov, A.A.; Pollakis, G.; Linnemann, T.; Kliphius, A.; Chalaby, M.I.; Paxton, W.A. Intrapatient alterations in the human immunodeficiency virus type 1 gp120 V1V2 and V3 regions differentially modulate coreceptor usage, virus inhibition by CC/CXC chemokines, soluble CD4, and the b12 and 2G12 monoclonal antibodies. J. Virol. 2004, 78, 524-530.
77. Doranz, B.J.; Lu, Z.H.; Rucker, J.; Zhang, T.Y.; Sharron, M.; Cen, Y.H.; Wang, Z.X.; Guo, H.H.; Du, J.G.; Accavitti, M.A.; Doms, R.W.; Peiper, S.C. Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1. J. Virol. 1997, 71, 6305-6314.
78. Picard, L.; Simmons, G.; Power, C.A.; Meyer, A.; Weiss, R.A.; Clapham, P.R. Multiple extracellular domains of CCR-5 contribute to human immunodeficiency virus type 1 entry and fusion. J. Virol. 1997, 71, 5003-5011.
79. Cormier, E.G.; Dragic, T. The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor. J. Virol. 2002, 76, 8953-8957.
80. Farzan, M.; Mirzabekov, T.; Kolchinsky, P.; Wyatt, R.; Cayabyab, M.; Gerard, N.P.; Gerard, C.; Sodroski, J.; Choe, H. Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell 1999, 96, 667-676.
81. Huang, C.C.; Tang, M.; Zhang, M.Y.; Majeed, S.; Montabana, E.; Stanfield, R.L.; Dimitrov, D.S.; Korber, B.; Sodroski, J.; Wilson, I.A.; Wyatt, R.; Kwong, P.D. Structure of a V3-containing HIV-1 gp120 core. Science 2005, 310, 1025-1028.
82. Christopoulos, A.; Kenakin, T. G protein-coupled receptor allosterism and complexing. Pharmacol. Rev. 2002, 54, 323-374.
83. Lee, B.; Sharron, M.; Blanpain, C.; Doranz, B.J.; Vakili, J.; Setoh, P.; Berg, E.; Liu, G.; Guy, H.R.; Durell, S.R.; Parmentier, M.; Chang, C.N.; Price, K.; Tsang, M.; Doms, R.W. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J. Biol. Chem. 1999, 274, 9617-9626.
84. Blanpain, C.; Vanderwinden, J.M.; Cihak, J.; Wittamer, V.; Le, P.E.; Issafras, H.; Stangassinger, M.; Vassart, G.; Marullo, S.; Schlndorff, D.; Parmentier, M.; Mack, M. Multiple active states and oligomerization of CCR5 revealed by functional properties of monoclonal antibodies. Mol. Biol. Cell 2002, 13, 723-737.
85. Hernanz-Falcon, P.; Rodriguez-Frade, J.M.; Serrano, A.; Juan, D.; del, S.A.; Soriano, S.F.; Roncal, F.; Gomez, L.; Valencia, A.; Martinez, A.; Mellado, M. Identification of amino acid residues crucial for chemokine receptor dimerization. Nat. Immunol. 2004, 5, 216-223.
86. Issafras, H.; Angers, S.; Bulenger, S.; Blanpain, C.; Parmentier, M.; Labbe-Jullie, C.; Bouvier, M.; Marullo, S. Constitutive agonist-independent CCR5 oligomerization and antibody-mediated clustering occurring at physiological levels of receptors. J. Biol. Chem. 2002, 277, 34666-34673.
87. Lin, P.F.; Blair, W.; Wang, T.; Spicer, T.; Guo, Q.; Zhou, N.; Gong, Y.F.; Wang, H.G.; Rose, R.; Yamanaka, G.; Robinson, B.; Li, C.B.; Fridell, R.; Deminie, C.; Demers, G.; Yang, Z.; Zadjura, L.; Meanwell, N.; Colonno, R. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc. Natl. Acad. Sci. U.S.A 2003, 100, 11013-11018.
88. Ho, H.T.; Fan, L.; Nowicka-Sans, B.; McAuliffe, B.; Li, C.B.; Yamanaka, G.; Zhou, N.; Fang, H.; Dicker, I.; Dalterio, R.; Gong, Y.F.; Wang, T.; Yin, Z.; Ueda, Y.; Matiskella, J.; Kadow, J.; Clapham, P.; Robinson, J.; Colonno, R.; Lin, P.F. Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events. J. Virol. 2006, 80, 4017-4025.
89. Malashkevich, V.N.; Chan, D.C.; Chutkowski, C.T.; Kim, P.S. Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: conserved helical interactions underlie the broad inhibitory activity of gp41 peptides. Proc. Natl. Acad. Sci. U.S.A 1998, 95, 9134-9139.
90. Joshi, S.B.; Dutch, R.E.; Lamb, R.A. A core trimer of the paramyxovirus fusion protein: parallels to influenza virus hemagglutinin and HIV-1 gp41. Virology 1998, 248, 20-34.
91. Wild, C.; Oas, T.; McDanal, C.; Bolognesi, D.; Matthews, T. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc. Natl. Acad. Sci. U.S.A 1992, 89, 10537-10541.
92. Kilby, J.M.; Hopkins, S.; Venetta, T.M.; DiMassimo, B.; Cloud, G.A.; Lee, J.Y.; Alldredge, L.; Hunter, E.; Lambert, D.; Bolognesi, D.; Matthews, T.; Johnson, M.R.; Nowak, M.A.; Shaw, G.M.; Saag, M.S. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 1998, 4, 1302-1307.
93. Lalezari, J.P.; Henry, K.; O'Hearn, M.; Montaner, J.S.; Piliero, P.J.; Trottier, B.; Walmsley, S.; Cohen, C.; Kuritzkes, D.R.; Eron, J.J., Jr.; Chung, J.; Demasi, R.; Donatacci, L.; Drobnes, C.; Delehanty, J.; Salgo, M. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med. 2003, 348, 2175-2185.
94. Rimsky, L.T.; Shugars, D.C.; Matthews, T.J. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J. Virol. 1998, 72, 986-993.
95. Wei, X.; Decker, J.M.; Liu, H.; Zhang, Z.; Arani, R.B.; Kilby, J.M.; Saag, M.S.; Wu, X.; Shaw, G.M.; Kappes, J.C. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 2002, 46, 1896-1905.
96. Lu, J.; Sista, P.; Giguel, F.; Greenberg, M.; Kuritzkes, D.R. Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). J. Virol. 2004, 78, 4628-4637.
97. Reeves, J.D.; Lee, F.H.; Miamidian, J.L.; Jabara, C.B.; Juntilla, M.M.; Doms, R.W. Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization. J. Virol. 2005, 79, 4991-4999.
98. Ray, N.; Harrison, J.E.; Blackburn, L.A.; Martin, J.N.; Deeks, S.G.; Doms, R.W. Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors. J. Virol. 2007, 81, 3240-3250.
99. Baldwin, C.E.; Sanders, R.W.; Deng, Y.; Jurriaans, S.; Lange, J.M.; Lu, M.; Berkhout, B. Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor. J. Virol. 2004, 78, 12428-12437.
100. Labrosse, B.; Morand-Joubert, L.; Goubard, A.; Rochas, S.; Labernardiere, J.L.; Pacanowski, J.; Meynard, J.L.; Hance, A.J.; Clavel, F.; Mammano, F. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients. J. Virol. 2006, 80, 8807-8819.
101. Derdeyn, C.A.; Decker, J.M.; Sfakianos, J.N.; Wu, X.; O'Brien, W.A.; Ratner, L.; Kappes, J.C.; Shaw, G.M.; Hunter, E. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. 2000, 74, 8358-8367.
102. Reeves, J.D.; Gallo, S.A.; Ahmad, N.; Miamidian, J.L.; Harvey, P.E.; Sharron, M.; Pohlmann, S.; Sfakianos, J.N.; Derdeyn, C.A.; Blumenthal, R.; Hunter, E.; Doms, R.W. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc. Natl. Acad. Sci. U.S.A 2002, 99, 16249-16254.
103. Reeves, J.D.; Miamidian, J.L.; Biscone, M.J.; Lee, F.H.; Ahmad, N.; Pierson, T.C.; Doms, R.W. Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity. J. Virol. 2004, 78, 5476-5485.
104. Biscone, M.J.; Miamidian, J.L.; Muchiri, J.M.; Baik, S.S.; Lee, F.H.; Doms, R.W.; Reeves, J.D. Functional impact of HIV coreceptor-binding site mutations. Virology 2006, 351, 226-236.
105. Tremblay, C.L.; Kollmann, C.; Giguel, F.; Chou, T.C.; Hirsch, M.S. Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100. J. Acquir. Immune. Defic. Syndr. 2000, 25, 99-102.
106. Zhang, X.Q.; Sorensen, M.; Fung, M.; Scoohley, R.T. Synergistic in vitro antiretroviral activity of a humanized monoclonal anti-CD4 antibody (TNX-355) and enfuvirtide (T-20). Antimicrob. Agents Chemother. 2006, 50, 2231-2233.
107. Nagashima, K.A.; Thompson, D.A.; Rosenfield, S.I.; Maddon, P.J.; Dragic, T.; Olson, W.C. Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. J. Infect. Dis. 2001, 183, 1121-1125.
108. Simmons, G.; Clapham, P.R.; Picard, L.; Offord, R.E.; Rosenkilde, M.M.; Schwartz, T.W.; Buser, R.; Wells, T.N.; Proudfoot, A.E. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 1997, 276, 276-279.
109. Townson, J.R.; Graham, G.J.; Landau, N.R.; Rasala, B.; Nibbs, R.J. Aminooxypentane addition to the chemokine macrophage inflammatory protein-1alpha P increases receptor affinities and HIV inhibition. J. Biol. Chem. 2000, 275, 39254-39261.
110. Blanpain, C.; Doranz, B.J.; Bondue, A.; Govaerts, C.; De, L.A.; Vassart, G.; Doms, R.W.; Proudfoot, A.; Parmentier, M. The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle. J. Biol. Chem. 2003, 278, 5179-5187.
111. Rodriguez-Frade, J.M.; Vila-Coro, A.J.; Martin, A.; Nieto, M.; Sanchez-Madrid, F.; Proudfoot, A.E.; Wells, T.N.; Martinez, A.; Mellado, M. Similarities and differences in RA. J. Cell Biol. 1999, 144, 755-765.
112. Signoret, N.; Pelchen-Matthews, A.; Mack, M.; Proudfoot, A.E.; Marsh, M. Endocytosis and recycling of the HIV coreceptor CCR5. J. Cell Biol. 2000, 151, 1281-1294.
113. Amara, A.; Gall, S.L.; Schwartz, O.; Salamero, J.; Montes, M.; Loetscher, P.; Baggiolini, M.; Virelizier, J.L.; Arenzana-Seisdedos, F. HIV coreceptor downregulation as antiviral principle: SDF-1alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication. J. Exp. Med. 1997, 186, 139-146.
114. Pastore, C.; Picchio, G.R.; Galimi, F.; Fish, R.; Hartley, O.; Offord, R.E.; Mosier, D.E. Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES. Antimicrob. Agents Chemother. 2003, 47, 509-517.
115. Brandt, S.M.; Mariani, R.; Holland, A.U.; Hope, T.J.; Landau, N.R. Association of chemokine-mediated block to HIV entry with coreceptor internalization. J. Biol. Chem. 2002, 277, 17291-17299.
116. Mack, M.; Luckow, B.; Nelson, P.J.; Cihak, J.; Simmons, G.; Clapham, P.R.; Signoret, N.; Marsh, M.; Stangassinger, M.; Borlat, F.; Wells, T.N.; Schlondorff, D.; Proudfoot, A.E. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J. Exp. Med. 1998, 187, 1215-1224.
117. Hartley, O.; Gaertner, H.; Wilken, J.; Thompson, D.; Fish, R.; Ramos, A.; Pastore, C.; Dufour, B.; Cerini, F.; Melotti, A.; Heveker, N.; Picard, L.; Alizon, M.; Mosier, D.; Kent, S.; Offord, R. Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors. Proc. Natl. Acad. Sci. U.S.A 2004, 101, 16460-16465.
118. Lederman, M.M.; Veazey, R.S.; Offord, R.; Mosier, D.E.; Dufour, J.; Mefford, M.; Piatak, M., Jr.; Lifson, J.D.; Salkowitz, J.R.; Rodriguez, B.; Blauvelt, A.; Hartley, O. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 2004, 306, 485-487.
119. Lobritz, M.A.; Ratcliff, A.N.; Marozsan, A.J.; Dudley, D.M.; Arts, E.J. XVIII International HIV Drug Resistance Workshop; June 9-13, 2009; Fort Myers, FL, USA; Abstract #12.
120. Vila-Coro, A.J.; Mellado, M.; Martin de, A.A.; Martinez, A.; Rodriguez-Frade, J.M. Characterization of RA. J. Immunol. 1999, 163, 3037-3044.
121. Marozsan, A.J.; Torre, V.S.; Johnson, M.; Ball, S.C.; Cross, J.V.; Templeton, D.J.; Quinones-Mateu, M.E.; Offord, R.E.; Arts, E.J. Mechanisms involved in stimulation of human immunodeficiency virus type 1 replication by aminooxypentane RANTES. J. Virol. 2001, 75, 8624-8638.
122. Gordon, C.J.; Muesing, M.A.; Proudfoot, A.E.; Power, C.A.; Moore, J.P.; Trkola, A. Enhancement of human immunodeficiency virus type 1 infection by the CC-chemokine RANTES is independent of the mechanism of virus-cell fusion. J. Virol. 1999, 73, 684-694.
123. Roscic-Mrkic, B.; Fischer, M.; Leemann, C.; Manrique, A.; Gordon, C.J.; Moore, J.P.; Proudfoot, A.E.; Trkola, A. RANTES (CCL5) uses the proteoglycan CD44 as an auxiliary receptor to mediate cellular activation signals and HIV-1 enhancement. Blood 2003, 102, 1169-1177.
124. Dragic, T.; Trkola, A.; Thompson, D.A.; Cormier, E.G.; Kajumo, F.A.; Maxwell, E.; Lin, S.W.; Ying, W.; Smith, S.O.; Sakmar, T.P.; Moore, J.P. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc. Natl. Acad. Sci. U. S. A 2000, 97, 5639-5644.
125. Tsamis, F.; Gavrilov, S.; Kajumo, F.; Seibert, C.; Kuhmann, S.; Ketas, T.; Trkola, A.; Palani, A.; Clader, J.W.; Tagat, J.R.; McCombie, S.; Baroudy, B.; Moore, J.P.; Sakmar, T.P.; Dragic, T. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J. Virol. 2003, 77, 5201-5208.
126. Veazey, R.S.; Klasse, P.J.; Ketas, T.J.; Reeves, J.D.; Piatak, M., Jr.; Kunstman, K.; Kuhmann, S.E.; Marx, P.A.; Lifson, J.D.; Dufour, J.; Mefford, M.; Pandrea, I.; Wolinsky, S.M.; Doms, R.W.; DeMartino, J.A.; Siciliano, S.J.; Lyons, K.; Springer, M.S.; Moore, J.P. Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. J. Exp. Med. 2003, 198, 1551-1562.
127. Veazey, R.S.; Springer, M.S.; Marx, P.A.; Dufour, J.; Klasse, P.J.; Moore, J.P. Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor. Nat. Med. 2005, 11, 1293-1294.
128. Dorr, P.; Westby, M.; Dobbs, S.; Griffin, P.; Irvine, B.; Macartney, M.; Mori, J.; Rickett, G.; Smith-Burchnell, C.; Napier, C.; Webster, R.; Armour, D.; Price, D.; Stammen, B.; Wood, A.; Perros, M. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 2005, 49, 4721-4732.
129. Kondru, R.; Zhang, J.; Ji, C.; Mirzadegan, T.; Rotstein, D.; Sankuratri, S.; Dioszegi, M. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol. Pharmacol. 2008, 73, 789-800.
130. Gulick, R.M.; Lalezari, J.; Goodrich, J.; Clumeck, N.; DeJesus, E.; Horban, A.; Nadler, J.; Clotet, B.; Karlsson, A.; Wohlfeiler, M.; Montana, J.B.; McHale, M.; Sullivan, J.; Ridgway, C.; Felstead, S.; Dunne, M.W.; van der Ryst, E.; Mayer, H. Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med. 2008, 359, 1429-1441.
131. Fatkenheuer, G.; Nelson, M.; Lazzarin, A.; Konourina, I.; Hoepelman, A.I.; Lampiris, H.; Hirschel, B.; Tebas, P.; Raffi, F.; Trottier, B.; Bellos, N.; Saag, M.; Cooper, D.A.; Westby, M.; Tawadrous, M.; Sullivan, J.F.; Ridgway, C.; Dunne, M.W.; Felstead, S.; Mayer, H.; van der Ryst, E. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N. Engl. J. Med. 2008, 359, 1442-1455.
132. McCarthy, M.; Suleiman, J.; Diaz, R.; Madruga, J.; DeJesus, E.; Zingman, B.; Slim, J.; Case, N.; Dunkle, L. 49th ICAAC; September 11-15, 2009; San Francisco, CA. Abstract H-923
133. Crabb, C. GlaxoSmithKline ends aplaviroc trials. AIDS 2006, 20, 641.
134. Marozsan, A.J.; Kuhmann, S.E.; Morgan, T.; Herrera, C.; Rivera-Troche, E.; Xu, S.; Baroudy, B. M.; Strizki, J.; Moore, J.P. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology 2005, 338, 182-199.
135. Trkola, A.; Kuhmann, S.E.; Strizki, J.M.; Maxwell, E.; Ketas, T.; Morgan, T.; Pugach, P.; Xu, S.; Wojcik, L.; Tagat, J.; Palani, A.; Shapiro, S.; Clader, J.W.; McCombie, S.; Reyes, G.R.; Baroudy, B.M.; Moore, J.P. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc. Natl. Acad. Sci. U.S.A 2002, 99, 395-400.
136. Westby, M.; Smith-Burchnell, C.; Mori, J.; Lewis, M.; Mosley, M.; Stockdale, M.; Dorr, P.; Ciaramella, G.; Perros, M. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J. Virol. 2007, 81, 2359-2371.
137. Baba, M.; Miyake, H.; Wang, X.; Okamoto, M.; Takashima, K. Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652. Antimicrob. Agents Chemother. 2007, 51, 707-715.
138. Westby, M.; Lewis, M.; Whitcomb, J.; Youle, M.; Pozniak, A.L.; James, I.T.; Jenkins, T.M.; Perros, M.; van der Ryst, E. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J. Virol. 2006, 80, 4909-4920.
139. Saag, M.; Goodrich, J.; Fatkenheuer, G.; Clotet, B.; Clumeck, N.; Sullivan, J.; Westby, M.; van der Ryst, E.; Mayer, H. A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J. Infect. Dis. 2009, 199, 1638-1647.
140. Kuhmann, S.E.; Pugach, P.; Kunstman, K.J.; Taylor, J.; Stanfield, R.L.; Snyder, A.; Strizki, J.M.; Riley, J.; Baroudy, B.M.; Wilson, I.A.; Korber, B.T.; Wolinsky, S.M.; Moore, J.P. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J. Virol. 2004, 78, 2790-2807.
141. Tsibris, A.M.; Sagar, M.; Gulick, R.M.; Su, Z.; Hughes, M.; Greaves, W.; Subramanian, M.; Flexner, C.; Giguel, F.; Leopold, K.E.; Coakley, E.; Kuritzkes, D.R. In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J. Virol. 2008, 82, 8210-8214.
142. Dudley, D.M.; Wentzel, J.L.; Lalonde, M.S.; Veazey, R.S.; Arts, E.J. Selection of a simian-human immunodeficiency virus strain resistant to a vaginal microbicide in macaques. J. Virol. 2009, 83, 5067-5076.
143. Mori, J.; Mosley, M.; Lewis, M.; Simpson, P.; Toma, J.; Huang, J. XVI International HIV Drug Resistance Workshop; June 12-16, 2007; Barbados; Abstract 10.
144. Pugach, P.; Marozsan, A.J.; Ketas, T.J.; Landes, E.L.; Moore, J.P.; Kuhmann, S.E. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 2007, 361, 212-228.
145. Anastassopoulou, C.G.; Ketas, T.J.; Klasse, P.J.; Moore, J.P. Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41. Proc. Natl. Acad. Sci. U.S.A 2009, 106, 5318-5323.
146. Ogert, R.A.; Wojcik, L.; Buontempo, C.; Ba, L.; Buontempo, P.; Ralston, R.; Strizki, J.; Howe, J.A. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. Virology 2008, 373, 387-399.
147. Anastassopoulou, C.G.; Marozsan, A.J.; Matet, A.; Snyder, A.D.; Arts, E.J.; Kuhmann, S.E.; Moore, J.P. Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness loss. PLoS. Pathog. 2007, 3, e79.
148. Torre, V.S.; Marozsan, A.J.; Albright, J.L.; Collins, K.R.; Hartley, O.; Offord, R.E.; Quinones-Mateu, M.E.; Arts, E.J. Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs. J. Virol. 2000, 74, 4868-4876.
149. Labrosse, B.; Labernardiere, J.L.; Dam, E.; Trouplin, V.; Skrabal, K.; Clavel, F.; Mammano, F. Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors. J. Virol. 2003, 77, 1610-1613.
150. Safarian, D.; Carnec, X.; Tsamis, F.; Kajumo, F.; Dragic, T. An anti-CCR5 monoclonal antibody and small molecule CCR5 antagonists synergize by inhibiting different stages of human immunodeficiency virus type 1 entry. Virology 2006, 352, 477-484.
151. Strizki, J.M.; Xu, S.; Wagner, N.E.; Wojcik, L.; Liu, J.; Hou, Y.; Endres, M.; Palani, A.; Shapiro, S.; Clader, J.W.; Greenlee, W.J.; Tagat, J.R.; McCombie, S.; Cox, K.; Fawzi, A.B.; Chou, C.C.; Pugliese-Sivo, C.; Davies, L.; Moreno, M.E.; Ho, D.D.; Trkola, A.; Stoddart, C.A.; Moore, J.P.; Reyes, G.R.; Baroudy, B.M. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A 2001, 98, 12718-12723.
152. Platt, E.J.; Durnin, J.P.; Kabat, D. Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus. J. Virol. 2005, 79, 4347-4356.
153. Mkrtchyan, S.R.; Markosyan, R.M.; Eadon, M.T.; Moore, J.P.; Melikyan, G.B.; Cohen, F.S. Ternary complex formation of human immunodeficiency virus type 1 Env, CD4, and chemokine receptor captured as an intermediate of membrane fusion. J. Virol. 2005, 79, 11161-11169.
154. Mosier, D.E.; Picchio, G.R.; Gulizia, R.J.; Sabbe, R.; Poignard, P.; Picard, L.; Offord, R.E.; Thompson, D.A.; Wilken, J. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. J. Virol. 1999, 73, 3544-3550.
155. Lobritz, M.A.; Marozsan, A.J.; Troyer, R.M.; Arts, E.J. Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivity. J. Virol. 2007, 81, 8258-8269.
156. Trkola, A.; Paxton, W.A.; Monard, S.P.; Hoxie, J.A.; Siani, M.A.; Thompson, D.A.; Wu, L.; Mackay, C.R.; Horuk, R.; Moore, J.P. Genetic subtype-independent inhibition of human immunodeficiency virus type 1 replication by CC and CXC chemokines. J. Virol. 1998, 72, 396-404.
157. Koning, F.A.; Kwa, D.; Boeser-Nunnink, B.; Dekker, J.; Vingerhoed, J.; Hiemstra, H.; Schuitemaker, H. Decreasing sensitivity to RANTES (regulated on activation, normally T cell-expressed and -secreted) neutralization of CC chemokine receptor 5-using, non-syncytium-inducing virus variants in the course of human immunodeficiency virus type 1 infection. J. Infect. Dis. 2003, 188, 864-872.
158. Kuhmann, S.E.; Platt, E.J.; Kozak, S.L.; Kabat, D. Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1. J. Virol. 2000, 74, 7005-7015.
159. Yang, X.; Kurteva, S.; Ren, X.; Lee, S.; Sodroski, J. Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1. J. Virol. 2005, 79, 12132-12147.
160. Yang, X.; Kurteva, S.; Ren, X.; Lee, S.; Sodroski, J. Subunit stoichiometry of human immunodeficiency virus type 1 envelope glycoprotein trimers during virus entry into host cells. J. Virol. 2006, 80, 4388-4395.
161. Layne, S.P.; Merges, M.J.; Dembo, M.; Spouge, J.L.; Nara, P.L. HIV requires multiple gp120 molecules for CD4-mediated infection. Nature 1990, 346, 277-279.
162. Herrera, C.; Klasse, P.J.; Kibler, C.W.; Michael, E.; Moore, J.P.; Beddows, S. Dominant-negative effect of hetero-oligomerization on the function of the human immunodeficiency virus type 1 envelope glycoprotein complex. Virology 2006, 351, 121-132.
163. Rangel, H.R.; Weber, J.; Chakraborty, B.; Gutierrez, A.; Marotta, M.L.; Mirza, M.; Kiser, P.; Martinez, M.A.; Este, J.A.; Quinones-Mateu, M.E. Role of the human immunodeficiency virus type 1 envelope gene in viral fitness. J. Virol. 2003, 77, 9069-9073.
164. Marozsan, A.J.; Moore, D.M.; Lobritz, M.A.; Fraundorf, E.; Abraha, A.; Reeves, J.D.; Arts, E.J. Differences in the fitness of two diverse wild-type human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry. J. Virol. 2005, 79, 7121-7134.
165. Domingo, E.; Holland, J.J. RNA virus mutations and fitness for survival. Annu. Rev. Microbiol. 1997, 51, 151-178.
166. Saag, M.S.; Hahn, B.H.; Gibbons, J.; Li, Y.; Parks, E.S.; Parks, W.P.; Shaw, G.M. Extensive variation of human immunodeficiency virus type-1 in vivo. Nature 1988, 334, 440-444.
167. Quinones-Mateu, M.E.; Ball, S.C.; Marozsan, A.J.; Torre, V.S.; Albright, J.L.; Vanham, G.; van Der, G.G.; Colebunders, R.L.; Arts, E.J. A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression. J. Virol. 2000, 74, 9222-9233.
168. Lassen, K.G.; Lobritz, M.A.; Bailey, J.R.; Johnston, S.; Nguyen, S.; Lee, B.; Chou, T.; Siliciano, R.F.; Markowitz, M.; Arts, E.J. Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics. PLoS. Pathog. 2009, 5, e1000377.